Date: 2015-11-27
Type of information: Nomination
Compound:
Company: Macrocure (Israel)
Therapeutic area: Cardiovascular diseases - Regenerative Medicine
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 27, 2015, Macrocure announced that as the Company continues to explore potential strategic alternatives, Tomer Kariv, a current Director on the Company\'s Board and CEO & Founder of Pontifax, will become Chairman of the Board replacing David Ben-Ami, current Chairman of the Company\'s Board of Directors, who will remain a member of Macrocure\'s Board of Directors. Mark Page, Chief Financial Officer, will be stepping down from his position at Macrocure by February 2016 to pursue other opportunities. Shai Lankry, current VP Finance and former CFO of Macrocure, will be assuming Mark\'s responsibilities. Dr. Michael Molyneaux, Chief Medical Officer, will also step down from his position in December. Macrocure has recently announced that pivotal phase 3 studies (MC-102 and MC-105) of CureXcell® in the treatment of diabetic foot ulcers (DFUs) and in the treatment of venous leg ulcers (VLU) did not meet its primary endpoint. The company is now exploring potential strategic alternatives.
Financial terms:
Latest news:
